

# William David Dotson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6992086/publications.pdf>

Version: 2024-02-01

31  
papers

1,762  
citations

304743

22  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health equity in the implementation of genomics and precision medicine: A public health imperative. <i>Genetics in Medicine</i> , 2022, 24, 1630-1639.	2.4	38
2	Challenges and Opportunities for Communication about the Role of Genomics in Public Health. <i>Public Health Genomics</i> , 2021, 24, 67-74.	1.0	3
3	From genes to public health: are we ready for DNA-based population screening?. <i>Genetics in Medicine</i> , 2021, 23, 996-998.	2.4	12
4	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz086.	2.9	39
5	Barriers and facilitators for cascade testing in genetic conditions: a systematic review. <i>European Journal of Human Genetics</i> , 2020, 28, 1631-1644.	2.8	55
6	Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework. <i>Genetics in Medicine</i> , 2019, 21, 28-37.	2.4	31
7	Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. <i>Genetics in Medicine</i> , 2018, 20, 428-434.	2.4	42
8	From public health genomics to precision public health: a 20-year journey. <i>Genetics in Medicine</i> , 2018, 20, 574-582.	2.4	109
9	Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. <i>Health Affairs</i> , 2018, 37, 801-808.	5.2	114
10	Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. <i>Genetics in Medicine</i> , 2017, 19, 890-899.	2.4	31
11	BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18–64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas – United States, 2009–2014. <i>MMWR Surveillance Summaries</i> , 2017, 66, 1-11.	34.6	33
12	A knowledge base for tracking the impact of genomics on population health. <i>Genetics in Medicine</i> , 2016, 18, 1312-1314.	2.4	17
13	Clinical utility of genetic and genomic services: context matters. <i>Genetics in Medicine</i> , 2016, 18, 672-674.	2.4	15
14	Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC). <i>Healthcare (Switzerland)</i> , 2015, 3, 830-837.	2.0	25
15	Public Awareness of Genetic Nondiscrimination Laws in Four States and Perceived Importance of Life Insurance Protections. <i>Journal of Genetic Counseling</i> , 2015, 24, 512-521.	1.6	47
16	Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. <i>Genetics in Medicine</i> , 2015, 17, 519-532.	2.4	26
17	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. <i>Genetics in Medicine</i> , 2015, 17, 63-67.	2.4	16
18	Horizon scanning for translational genomic research beyond bench to bedside. <i>Genetics in Medicine</i> , 2014, 16, 535-538.	2.4	28

#	ARTICLE	IF	CITATIONS
19	Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 394-402.	4.7	53
20	Beyond Base Pairs to Bedside: A Population Perspective on How Genomics Can Improve Health. <i>American Journal of Public Health</i> , 2012, 102, 34-37.	2.7	51
21	Knowledge integration at the center of genomic medicine. <i>Genetics in Medicine</i> , 2012, 14, 643-647.	2.4	26
22	Horizon scanning for new genomic tests. <i>Genetics in Medicine</i> , 2011, 13, 161-165.	2.4	39
23	Is there a need for PCxceptionalism?. <i>Genetics in Medicine</i> , 2011, 13, 866-867.	2.4	13
24	Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategiesâ€”A targeted evidence-based review. <i>Genetics in Medicine</i> , 2010, 12, 772-784.	2.4	32
25	Outcomes of interest in evidence-based evaluations of genetic tests. <i>Genetics in Medicine</i> , 2010, 12, 228-235.	2.4	82
26	Tumor Gene Expression Profiling in Women with Breast Cancer Test Category: Prognostic. <i>PLOS Currents</i> , 2010, 2, RRN1178.	1.4	1
27	PLoS Currents: Evidence on Genomic Tests â€” At the Crossroads of Translation. <i>PLOS Currents</i> , 2010, 2, RRN1179.	1.4	6
28	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. <i>Genetics in Medicine</i> , 2009, 11, 21-34.	2.4	135
29	The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. <i>Genetics in Medicine</i> , 2009, 11, 3-14.	2.4	584
30	The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. , 2009, , 458-481.		3
31	Identification of a UPC2 Homolog in <i>Saccharomyces cerevisiae</i> and Its Involvement in Aerobic Sterol Uptake. <i>Journal of Bacteriology</i> , 2001, 183, 830-834.	2.2	56